Nimenrix

Meningococcal polysaccharide serogroups A, C, W-135 & Y conjugate vaccine

Active immunization against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 & Y in individuals from 6 wk of age.

IM Adult, adolescent & childn from 12 mth Primary immunization: 0.5 mL single dose. Unvaccinated infant from 6-<12 mth Primary immunization: 0.5 mL single dose from 6 mth. Booster: At 12 mth w/ min interval of at least 2 mth after the primary dose. Infant from 6 wk-<6 mth Primary immunization: 2 doses of 0.5 mL, w/ the 1st dose given from 6 wk w/ an interval of 2 mth between doses. Booster: At 12 mth.

Hypersensitivity.

Do not administer intravascularly, intradermally or SC. Postpone vaccination in patients w/ acute severe febrile illness. Syncope. Patients w/ thrombocytopenia or any coagulation disorder. May not elicit adequate immune response in patients receiving immunosuppressive treatment or w/ immunodeficiency. Increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W-135, & Y even if Abs were developed following vaccination in patients w/ certain complement deficiencies & those receiving treatment that inhibits terminal complement activation (eg, eculizumab). Patients w/ increased susceptibility to meningococcal infection due to anatomic or functional asplenia (eg, sickle cell disease). Do not have protection against other Neisseria meningitidis groups. Not all vaccinees may elicit a protective immune response. Consider administering a 2nd primary dose after an interval of 2 mth if an infant (6-<12 mth) or toddler (12-14 mth) is expected to be at immediate risk of invasive meningococcal disease due to exposure to groups W-135 &/or Y. Consider administering a booster dose if an individual is expected to be at particular risk of exposure to group A & received dose approx >1 yr previously; in individuals remaining at high risk of exposure to meningococcal disease caused by groups A, C, W-135, & Y. Not a substitute for tetanus immunization. Pregnancy & lactation.

Appetite loss; irritability, insomnia, crying; drowsiness, headache, hypoesthesia, dizziness; GI symptoms (including diarrhea, vomiting & nausea); rash, urticaria, pruritus; myalgia, pain in extremity; fever, swelling, pain & redness at inj site, fatigue, inj site hematoma, malaise, inj site reaction (including induration, pruritus, warmth, anesth), extensive limb swelling at the inj site.

Tetanus toxoid (TT) containing vaccine eg, DTaP/IPV/Hib/HepB vaccine (administer at least 1 mth before TT-containing vaccine). May not elicit adequate response w/ immunosuppressive treatment.

Vaccines, Antisera & Immunologicals

J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.

Rx